UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen
UKONIQ is approved for adult patients with relapsed or refractory follicular lymphoma after at least three prior lines of systemic therapy
UKONIQ is the first and only inhibitor of PI3K-delta and CK1-epsilon for relapsed/refractory MZL and FL
U.S. Commercial launch now underway
Company to host conference call on Monday, February 8, 2021 at 8:30 AM ET
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.(NASDAQ: TGTX), today announced theU.S. Food and Drug Administration(FDA) has approved UKONIQ (umbralisib), for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen and adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
UKONIQ is the first and only, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon. Accelerated approval was granted for these indications based on overall response rate (ORR) data from the Phase 2 UNITY-NHL Trial (NCT02793583). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial.This application was granted priority review for the MZL indication. In addition, UKONIQ was granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.
Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, Todays approval of UKONIQ marks a historic day for our Company with this being our first approval and we are extremely pleased to be able to bring our novel inhibitor of PI3K-delta and CK1-epsilon to patients with relapsed/refractory MZL and FL. We have built a commercial team with significant experience who will immediately start to engage our customers to educate them on UKONIQ and how to access the product for patients in needand expect to make UKONIQ available to US distributors in the next few days. Mr. Weiss continued, We want to thank the patients, physicians, nurses and clinical coordinators for their support and participation in our clinical trials, and the FDA for their collaboration throughout this process. We remain dedicated to patients with B-cell diseases and our mission of developing treatment options for those in need.
Despite treatment advances, MZL and FL remain incurable diseases with limited treatment options for patients who relapse after prior therapy and no defined standard of care. With the approval ofumbralisib we now have a targeted, oral, once-daily option, offering a needed treatment alternative for patients, stated Dr. Nathan Fowler, Professor of Medicine at The University of Texas MD Anderson Cancer Center and the Study Chair of the UNITY-NHL MZL &FL cohorts.
The approval ofumbralisib for the treatment of relapsed/refractory marginal zone lymphoma and follicular lymphoma offers patients a new treatment option, and new hope in the fight against these diseases, stated Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
EFFICACY & SAFETY DATA IN RELAPSED/REFRACTORY MZL AND FLThe efficacy of UKONIQ monotherapy was evaluated in two single-arm cohorts, within the Phase 2 UNITY-NHL clinical trial, in 69 patients with MZL who received at least 1 prior therapy, including an anti-CD20 regimen, and in 117 patients with FL who received at least 2 prior systemic therapies, including an anti-CD20 monoclonal antibody and an alkylating agent. The UNITY-NHL Phase 2 trial is an open-label, multi-center, multi-cohort study with patients receiving UKONIQ 800 mg once daily. The primary endpoint was independent review committee (IRC) assessed overall response rate (ORR) according to the Revised International Working Group Criteria.
CI, confidence interval; NR, not reached; NE, not evaluable +Denotes censored observation
The safety of UKONIQ monotherapy was based on a pooled population from the 221 adults with MZL and FL in three single arm, open label trials and one open label extension trial. Patients received UKONIQ 800 mg orally once daily. Serious adverse reactions occurred in 18% of patients who received UKONIQ. Serious adverse reactions that occurred in 2% of patients were diarrhea-colitis (4%), pneumonia (3%), sepsis (2%), and urinary tract infection (2%). The most common adverse reactions (>15%), including laboratory abnormalities, were increased creatinine (79%), diarrhea-colitis (58%, 2%), fatigue (41%), nausea (38%), neutropenia (33%), ALT increase (33%), AST increase (32%), musculoskeletal pain (27%), anemia (27%), thrombocytopenia (26%), upper respiratory tract infection (21%), vomiting (21%), abdominal pain (19%), decreased appetite (19%), and rash (18%).
ABOUT UKONIQ(umbralisib) 200 MG TABLETSUKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon. PI3K-deltais known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking and immunity and is expressed in both normal and malignant B-cells. CK1-epsilonis a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
IMPORTANT SAFETY INFORMATIONInfections: Serious, including fatal, infections occurred in patients treated with UKONIQ. Grade 3 or higher infections occurred in 10%of 335 patients, with fatal infections occurring in <1%. The most frequent Grade 3 infections included pneumonia, sepsis, and urinary tract infection. Provide prophylaxis for Pneumocystis jirovecii pneumonia (PJP) and consider prophylactic antivirals during treatment with UKONIQ to prevent CMV infection, including CMV reactivation. Monitor for any new or worsening signs and symptoms of infection, including suspected PJP or CMV, during treatment with UKONIQ. For Grade 3 or 4 infection, withhold UKONIQ until infection has resolved. Resume UKONIQ at the same or a reduced dose. Withhold UKONIQ in patients with suspected PJP of any grade and permanently discontinue in patients with confirmed PJP. For clinical CMV infection or viremia, withhold UKONIQ until infection or viremia resolves. If UKONIQ is resumed, administer the same or reduced dose and monitor patients for CMV reactivation by PCR or antigen test at least monthly.
Neutropenia: Serious neutropenia occurred in patients treated with UKONIQ. Grade 3 neutropenia developed in 9% of 335 patients and Grade 4 neutropenia developed in 9%. Monitor neutrophil counts at least every 2 weeks for the first 2 months of UKONIQ and at least weekly in patients with neutrophil count <1 x 109/L (Grade 3-4) neutropenia during treatment with UKONIQ. Consider supportive care as appropriate. Withhold, reduce dose, or discontinue UKONIQ depending on the severity and persistence of neutropenia.
Diarrhea or Non-Infectious Colitis: Serious diarrhea or non-infectious colitis occurred in patients treated with UKONIQ. Any grade diarrhea or colitis occurred in 53% of 335 patients and Grade 3 occurred in 9%.For patients with severe diarrhea (Grade 3, i.e., > 6 stools per day over baseline) or abdominal pain, stool with mucus or blood, change in bowel habits, or peritoneal signs, withhold UKONIQ until resolved and provide supportive care with antidiarrheals or enteric acting steroids as appropriate. Upon resolution, resume UKONIQ at a reduced dose. For recurrent Grade 3 diarrhea or recurrent colitis of any grade, discontinue UKONIQ. Discontinue UKONIQ for life-threatening diarrhea or colitis.
Hepatotoxicity: Serious hepatotoxicityoccurred in patients treated with UKONIQ. Grade 3 and 4 transaminase elevations (ALT and/or AST) occurred in 8% and <1%, respectively, in 335 patients. Monitor hepatic function at baseline and during treatment with UKONIQ. For ALT/AST greater than 5 to less than 20 times ULN, withhold UKONIQ until return to less than 3 times ULN, then resume at a reduced dose. For ALT/AST elevation greater than 20 times ULN, discontinue UKONIQ.
Severe Cutaneous Reactions: Severe cutaneous reactions, including a fatal case of exfoliative dermatitis, occurred in patients treated with UKONIQ. Grade 3 cutaneous reactions occurred in 2% of 335 patients and included exfoliative dermatitis, erythema, and rash (primarily maculo-papular). Monitor patients for new or worsening cutaneous reactions. Review all concomitant medications and discontinue any potentially contributing medications. Withhold UKONIQ for severe (Grade 3) cutaneous reactions until resolution. Monitor at least weekly until resolved. Upon resolution, resume UKONIQ at a reduced dose. Discontinue UKONIQ if severe cutaneous reaction does not improve, worsens, or recurs. Discontinue UKONIQ for life-threatening cutaneous reactions or SJS, TEN, or DRESS of any grade. Provide supportive care as appropriate.
Allergic Reactions Due to Inactive Ingredient FD&C Yellow No. 5: UKONIQ contains FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, frequently in patients who also have aspirin hypersensitivity.
Embryo-fetal Toxicity: Based on findings in animals and its mechanism of action, UKONIQ can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males with female partners of reproductive potential to use effective contraception during treatment and for at least one month after the last dose.
Serious adverse reactions occurred in 18% of 221 patients who received UKONIQ. Serious adverse reactions that occurred in 2% of patients were diarrhea-colitis (4%), pneumonia (3%), sepsis (2%), and urinary tract infection (2%). Permanent discontinuation of UKONIQ due to an adverse reaction occurred in 14% of patients. Dose reductions of UKONIQ due to an adverse reaction occurred in 11% of patients. Dosage interruptions of UKONIQ due to an adverse reaction occurred in 43% of patients.
The most common adverse reactions (>15%), including laboratory abnormalities, in 221 patients who received UKONIQ were increased creatinine (79%), diarrhea-colitis (58%, 2%), fatigue (41%), nausea (38%), neutropenia (33%), ALT increase (33%), AST increase (32%), musculoskeletal pain (27%), anemia (27%), thrombocytopenia (26%), upper respiratory tract infection (21%), vomiting (21%), abdominal pain (19%), decreased appetite (19%), and rash (18%).
Lactation: Because of the potential for serious adverse reactions from umbralisib in the breastfed child, advise women not to breastfeed during treatment with UKONIQ and for at least one month after the last dose.
Please visit http://www.tgtherapeutics.com/prescribing-information/uspi-ukon for full Prescribing Information and Medication Guide.
Physicians, pharmacists, or other healthcare professionals with questions about UKONIQ should visitwww.UKONIQ.com.
ABOUT TG PATIENT SUPPORTThe TG Patient Support is a comprehensive program designed by TG Therapeutics to support patients through their treatment journey and the reimbursement process. More information about the TG Patient Support program is accessible by phone at 1-877-TGTXPSP (1-877-848-9777); by fax at 1-877-778-1329 or at http://www.UKONIQ.com/patient/patientsupport.
ABOUT MARGINAL ZONE LYMPHOMAMarginal zone lymphoma (MZL) comprises a group of indolent (slow growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL is generally considered a chronic and incurable disease. With an annual incidence of approximately 8,200 newly diagnosed patients in the United States1,2, MZL is the third most common B-cell NHL, accounting for approximately ten percent of all NHL cases. MZL consists of three different subtypes: extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL)3.
ABOUT FOLLICULAR LYMPHOMAFollicular lymphoma (FL) is typically an indolent form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes. It is the second most common form of NHL. FL is generally not curable and is considered a chronic disease, as patients can live for many years with this form of lymphoma.With an annual incidence inthe United Statesof approximately 13,200 newly diagnosed patients1,2, FL is the most common indolent lymphoma accounting for approximately 17 percent of all NHL cases4.
CONFERENCE CALL INFORMATIONThe Company will host a conference call on Monday, February 8, 2021 at 8:30 AM ET to discuss the UKONIQ approval. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside theU.S.), Conference Title: TG Therapeutics. A live webcast will be available on the Events page, located within the Investors & Media section, of the Company's website atwww.tgtherapeutics.com. An audio recording of the conference call will also be available for replay atwww.tgtherapeutics.com, for a period of 30 days after the call.
ABOUT TG THERAPEUTICS, INC.TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.For more information, visit http://www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.UKONIQTM is a registered trademark of TG Therapeutics, Inc.
__________________________________________________
1National Cancer Institute. SEER Cancer Statistics Review 2008-2017: Non-Hodgkin Lymphoma. Table 19.26. https://seer.cancer.gov/csr/1975_2017/results_single/sect_19_table.26_2pgs.pdf. Accessed January 19, 2021.2National Cancer Institute. SEER Cancer Stat Facts: Non-Hodgkin Lymphoma. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed January 19, 2021.3Lymphoma Research Foundation: Marginal Zone Lymphomahttps://lymphoma.org/aboutlymphoma/nhl/mzl/4Lymphoma Research FoundationFollicular Lymphoma
Cautionary StatementThis press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Such forward looking statements include but are not limited to statements regarding expectations for the timing and commercial launch and availability of UKONIQ (umbralisib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) and follicular lymphoma (FL); clinical trials, including the confirmatory trial for UKONIQ in R/R MZL and FL; and anticipated healthcare professional and patient acceptance and use of UKONIQ for the FDA-approved indications.
In addition to the risk factors identified from time to time in our reports filed with theSecurities and Exchange Commission, factors that could cause our actual results to differ materially include the following: the Companys ability to establish and maintain a commercial infrastructure, and to successfully launch, market and sell UKONIQ or future products, if approved; failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, such as the submission of sufficient data from a confirmatory clinical study; the potential for variation from the Companys projections and estimates about the potential market for UKONIQ or the Companys product candidates due to a number of factors, including for example, limitations that regulators may impose on the required labeling for the proposed treatment population for UKONIQ or our other product candidates; the Companys ability to meet post-approval compliance obligations (on topics including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); potential regulatory challenges to the Companys plans to seek expanded or additional indications for UKONIQ in the U.S. or plans to seek marketing approval for the product in additional geographies, outside of the U.S.; the Companys reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for its clinical and commercial products, including UKONIQ; the uncertainties inherent in research and development; and the risk that the ongoing COVID-19 pandemic and associated government control measures have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year endedDecember 31, 2019and in our other filings with theU.S. Securities and Exchange Commission.
Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available atwww.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
PDF attachments accompanying this release are available at
http://ml.globenewswire.com/Resource/Download/e3586449-8f68-4532-aa66-9d93452ec247
http://ml.globenewswire.com/Resource/Download/c6b34caf-fefa-4014-80ec-bb9404c86fff
http://ml.globenewswire.com/Resource/Download/590c4cb8-995f-4a5b-99a0-f087cfc88833
http://ml.globenewswire.com/Resource/Download/6da473d8-7630-44cf-9bd5-c48d6246c467
More here:
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ (umbralisib) - GlobeNewswire
- More Stem Cells Extracted For Later Use For My MS [Last Updated On: March 14th, 2011] [Originally Added On: March 14th, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: April 2nd, 2011] [Originally Added On: April 2nd, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: April 3rd, 2011] [Originally Added On: April 3rd, 2011]
- Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science [Last Updated On: April 6th, 2011] [Originally Added On: April 6th, 2011]
- Stem Cell Patient Richard H. MS Treatment [Last Updated On: May 20th, 2011] [Originally Added On: May 20th, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- Dr. Janet Rossant, Premier's Summit Award 2010 recipient [Last Updated On: May 31st, 2011] [Originally Added On: May 31st, 2011]
- Visions Episode 92: Stem Cells Discovery [Last Updated On: May 31st, 2011] [Originally Added On: May 31st, 2011]
- PROSTATE CANCER and stem cells.wmv [Last Updated On: June 9th, 2011] [Originally Added On: June 9th, 2011]
- Stem Cells Used to Grow Windpipes [Last Updated On: June 10th, 2011] [Originally Added On: June 10th, 2011]
- Visions Episode 92: Stem Cells Discovery [Last Updated On: July 12th, 2011] [Originally Added On: July 12th, 2011]
- PROSTATE CANCER and stem cells [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Doctors Use Stem Cells to Grow New Windpipes [Last Updated On: August 29th, 2011] [Originally Added On: August 29th, 2011]
- Sims 2 Mafia Story Part 7 - Farewell, Godfather/Stem Cell Medicine [Last Updated On: August 30th, 2011] [Originally Added On: August 30th, 2011]
- Regenerative Medicine: Pathways to Cure - Version 2.0 [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Stem Cell Research: Huntington's Disease [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Adult Stem Cell Therapy for COPD: One Man's Story [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Stem Cell Update from Panama 3 Years Later [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem Cell Update from Panama 3 Years Later [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Regenerative Medicine and Applications of Stem Cell Research [Last Updated On: October 10th, 2011] [Originally Added On: October 10th, 2011]
- Stem Cell Therapy for Sickle Cell Anemia - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Stem_Cell_Therapy_for_ALS.wmv - Video [Last Updated On: October 17th, 2011] [Originally Added On: October 17th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Stem Cells: The Hope The Hype and the Science - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- What are stem cells? How can they be used for medical benefit? - Video [Last Updated On: October 24th, 2011] [Originally Added On: October 24th, 2011]
- What are stem cells? How can they be used for medical benefit? - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- The CIRM Creativity Awards: Training 21st Century Stem Cell Scientists - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- What Organ Shortage? Just Make Your Own! Stem Cells and Organ Engineering - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: November 9th, 2011] [Originally Added On: November 9th, 2011]
- StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- Alumni Profile: Dr. John Tisdale, NIH Researcher, Stem Cell Transplants and Sickle Cell - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Intel co-founder Andrew Grove gives keynote at 2011 World Stem Cell Summit in Pasadena - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- Austin Forum - Nov 1st (Highlights) - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- Dr. Jordan Pomeroy discusses xeno-Free Derivation and Maintenance of Pluripotent Cell Lines - Video [Last Updated On: November 19th, 2011] [Originally Added On: November 19th, 2011]
- So Many Chemicals...So Little Time: Stem Cell Research and Environmental Health - Video [Last Updated On: November 19th, 2011] [Originally Added On: November 19th, 2011]
- Austin Forum - Nov 1st (Part 4 of 4) - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- Austin Forum - Nov 1st (Part 2 of 4) - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- Austin Forum - Nov 1st (Part 1 of 4) - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- Alan Trounson: Are stem cells the end of disease? - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- Alan Trounson: Are stem cells the end of disease? - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- A4M Stem Cell Fellowship Module II Preview - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- Auxogyn_ASRM_FINAL.mov - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Bruce Lipton,making the connections part 1 - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- Assessment of Embryo Viability (Auxogyn_ASRM_First Prize) - Video [Last Updated On: December 4th, 2011] [Originally Added On: December 4th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- NAMCP 2011: Ravi Vij, MD, Associate Professor of Medicine, Washington University School of Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- Future360 - Alan Trounson, CEO of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 2011 World Stem Cell Summit Open Comments [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 2011 Summit: Keynote Address, CIRM's Translational Roadmap to Stem Cell Cures, Alan Trounson, PhD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 2011 Summit: Government [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- Autism Stem Cell Trip - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- GeneCell International Dental Pulp Stem Cell's Banking Services - Video [Last Updated On: December 21st, 2011] [Originally Added On: December 21st, 2011]
- GeneCell International Dental Pulp Stem Cell's Banking Services - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video [Last Updated On: January 2nd, 2012] [Originally Added On: January 2nd, 2012]
- Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium Attracts a World Class Faculty to New ... [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Lecture by stem cell researcher tomorrow [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- Biobanking for Medicine: Technology and Market 2012-2022 [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 'Personalized medicine' gets $67.5M research boost [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Dr. Ramaswamy on Targeting Dormant Cancer Cells - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Daniel Kraft on Singularity 1 on 1 (part 3) - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Daniel Kraft on Singularity 1 on 1 (part 1) - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Statement - Rx&D Applauds Government of Canada for Investing in Personalized Medicine [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Molecules to Medicine: Plan B: The Tradition of Politics at the FDA [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- 'Personalized medicine' gets $67.5M research boost [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- The Pet Corner: Behold! The future of modern medicine is here [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Molecules to Medicine: Plan B: The Tradition of Politics at the FDA [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Treating Brain Injuries With Stem Cell Transplants - Promising Results [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Stem Cells to Treat Acne Scarring | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: February 6th, 2012] [Originally Added On: February 6th, 2012]
- American CryoStem Completes Cell Processing for Clinical Study [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports ... [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Meet the Founders of Cord Blood Registry - Video [Last Updated On: February 9th, 2012] [Originally Added On: February 9th, 2012]